A61K 38/50
Acting on carbon-nitrogen bonds, other than peptide bonds
Official title: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K38/50 (Acting on carbon-nitrogen bonds, other than peptide bonds) appears on 402 US grants and 752 published applications in this corpus.
Search patents in A61K- Granted patents
- 402
- Published applications
- 752
- Assignees
- 373
- Inventors
- 1,197
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 6 | 0 |
| 2001 | 10 | 1 |
| 2002 | 5 | 9 |
| 2003 | 4 | 9 |
| 2004 | 5 | 16 |
| 2005 | 2 | 12 |
| 2006 | 3 | 12 |
| 2007 | 4 | 21 |
| 2008 | 2 | 27 |
| 2009 | 3 | 19 |
| 2010 | 6 | 16 |
| 2011 | 6 | 19 |
| 2012 | 7 | 11 |
| 2013 | 11 | 29 |
| 2014 | 21 | 24 |
| 2015 | 22 | 49 |
| 2016 | 18 | 47 |
| 2017 | 30 | 34 |
| 2018 | 30 | 43 |
| 2019 | 26 | 50 |
| 2020 | 31 | 41 |
| 2021 | 29 | 50 |
| 2022 | 24 | 66 |
| 2023 | 13 | 41 |
| 2024 | 19 | 34 |
| 2025 | 22 | 38 |
| 2026 | 18 | 34 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Enumeration of genetically engineered microorganisms by live cell counting techniques1 Sep 2026US 12,721,882 B2Synlogic Operating Company, Inc.
- Methods and compositions for rejuvenating CNS glial populations by suppresion of transcription factors21 Jul 2026US 12,686,868 B2University of Rochester
- Asparaginase-based cancer therapy7 Jul 2026US 12,673,092 B2Kyon Biotech AG
- Method and composition for treating arginase 1 deficiency7 Jul 2026US 12,673,093 B2Immedica Pharma AB
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Method and composition for treating arginase 1 deficiency24 Sep 2026US 2026/0284160 A1Immedica Pharma AB
- Asparaginase-based cancer therapy17 Sep 2026US 2026/0273031 A1Kyon Biotech AG
- Compositions and methods for altering complement activation10 Sep 2026US 2026/0263501 A1Apellis Pharmaceuticals, Inc.
- Base editing proteins and uses thereof27 Aug 2026US 2026/0250650 A1
Most cited
By later US patents
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- RNA containing modified nucleosides and methods of use thereof230US 8,691,966 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof222US 8,748,089 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof198US 8,835,108 B2The Trustees of the University of Pennsylvania · 2014
- Antibody formulations and methods of making same140US 8,420,081 B2AbbVie Inc. · 2013